People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology, Healthtech, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Poseida Therapeutics, Inc. | — | Biotechnology | Series D+ | $231.8M | $369.6M | 2018 |
| Ceresti Health, Inc. | — | Healthtech | Series A | $28.2M | $38.9M | 2025 |
| Aperio Technologies Inc | — | Other Health Care | Series A | $16.3M | $117.4M | 2012 |
Mark Gergen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Gergen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dirk Soenksen | 2 | 3 |
| David Hirsch | 1 | 16 |
| Zubeen Shroff | 1 | 5 |
| Martin Felsenthal | 1 | 5 |
| Patrick Yount | 1 | 4 |
| Steve Baloff | 1 | 4 |
| Tom Rodgers | 1 | 4 |
| Kevin Liang | 1 | 2 |
| Lars Ekman | 1 | 2 |
| Charles M. Baum | 1 | 2 |
| Brent J. Warner | 1 | 2 |
| Catherine J. Mackey | 1 | 2 |
| Mark J. Gergen | 1 | 2 |
| Matthew Spear | 1 | 1 |
| Mark Wrenn | 1 | 1 |
| David Morehead | 1 | 1 |
| Christopher Ciano | 1 | 1 |
| Tom Bologna | 1 | 1 |
| Adrian Howd | 1 | 1 |
| Harry J. Leonhardt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.